多形性胶质母细胞瘤治疗市场规模、份额、成长分析，按治疗类型、最终用户、地区划分 - 产业预测，2024-2031

2022年，多形性胶质母细胞瘤治疗的全球市场规模为24.6亿美元，从2023年的27亿美元增长到2031年的56.6亿美元，在预测期内（2024-2031年）预计将以复合年增长率成长。

由于胶质母细胞瘤病例的快速增加以及对研究和开发的日益关注，预计多形性胶质母细胞瘤治疗市场将显着成长。全球癌症观察站的令人震惊的统计数据显示，2020 年脑癌死亡人数超过 251,000 人，确诊人数超过 308,000 人，大型製药企业正在加大产品平臺。根据世界卫生组织 2021 年发布的证据，脑癌病例超过 245,000 例，增加了对有效治疗方案的需求。然而，市场面临障碍，包括高昂的治疗成本以及开发针对这种侵袭性癌症的有效治疗方法的挑战。然而，在个人化医疗的进步和有希望的临床试验结果的推动下，免疫疗法、标靶治疗和创新联合治疗的机会比比皆是。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析与影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析
• 案例研究

按治疗类型分類的多形性胶质母细胞瘤治疗市场规模

• 市场概况
• 化疗
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • 其他的
• 放射治疗
  • 外部放射治疗（EBRT）
  • 放射线治疗
• 标靶治疗
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂
• 免疫疗法
  • 查核点抑制剂
  • 疫苗治疗
• 肿瘤治疗电场（TTF）疗法
• 外科手术
  • 开颅手术
  • 切片检查

多形性胶质母细胞瘤治疗市场规模：依最终用户划分

• 市场概况
• 医院
• 诊所
• 门诊手术中心
• 调查机构

按地区分類的多形性胶质母细胞瘤治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Roche Holding AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Amgen Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Sanofi SA
• Bayer AG
• AstraZeneca plc
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline plc
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Ipsen SA
• Sumitomo Dainippon Pharma Co., Ltd.
• Karyopharm Therapeutics Inc.

结论和建议

Global Glioblastoma Multiforme Treatment Market size was valued at USD 2.46 billion in 2022 and is poised to grow from USD 2.70 billion in 2023 to USD 5.66 billion by 2031, growing at a CAGR of 9.7% during the forecast period (2024-2031).

The glioblastoma multiforme treatment market is poised for substantial growth, driven by a surge in glioblastoma cases and a heightened focus on research and development. Major pharmaceutical companies are bolstering their product pipelines, responding to the alarming statistics from the Global Cancer Observatory, which noted over 251,000 deaths and 308,000 diagnoses of brain cancers in 2020. Added evidence from the WHO in 2021 highlighted more than 245,000 occurrences of such tumors, amplifying the need for effective treatment options. However, the market faces hurdles, including high treatment costs and the challenge of developing effective therapies for this aggressive cancer. Nevertheless, opportunities abound in immunotherapy, targeted treatments, and innovative combinations, fueled by advancements in personalized medicine and promising clinical trial outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glioblastoma Multiforme Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glioblastoma Multiforme Treatment Market Segmental Analysis

Global Glioblastoma Multiforme Treatment Market is segmented by treatment type, end user and region. Based on treatment type, the market is segmented into chemotherapy (temozolomide, bevacizumab, carmustine, lomustine, others), radiation therapy (external beam radiation therapy (EBRT), brachytherapy), targeted therapy (monoclonal antibodies, tyrosine kinase inhibitors), immunotherapy (checkpoint inhibitors, vaccine therapy), tumor treating fields (TTF) therapy and surgery (craniotomy, biopsy). Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market is primarily driven by several key factors. The increasing prevalence of glioblastoma, a particularly aggressive form of brain cancer, continues to spur demand for effective treatment options. Advancements in medical technology and innovative therapeutic approaches, such as targeted therapies and immunotherapy, are enhancing treatment efficacy and patient outcomes. Additionally, rising investments in research and development, along with the growing focus on personalized medicine, are fostering the introduction of new drugs and therapies into the market. Moreover, heightened awareness of glioblastoma and improved access to healthcare services are contributing to market expansion globally.

Restraints in the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme Treatment market faces several constraints that could hinder its growth. Key challenges include the high costs associated with treatment options, which may limit access for many patients. Additionally, the complex nature of glioblastoma, characterized by its aggressive behavior and resistance to conventional therapies, presents a significant barrier to effective treatment. Furthermore, a lack of robust clinical data and ongoing research may delay the introduction of new and innovative therapies. Regulatory hurdles and the need for extensive clinical trials can also impede market expansion, while the limited number of healthcare professionals specializing in this area adds to the market's challenges.

Market Trends of the Global Glioblastoma Multiforme Treatment Market

The Global Glioblastoma Multiforme (GBM) Treatment market is witnessing a significant trend towards increased adoption of personalized medicine, revolutionizing standard treatment paradigms. This shift leverages advancements in genetic profiling and biomarker testing, enabling healthcare providers to tailor therapies to the unique characteristics of each patient's tumor. Such precision approaches not only enhance treatment efficacy but also minimize the risk of adverse effects, reflecting a broader movement towards individualized healthcare solutions. As stakeholders invest in research and technology to develop targeted therapies, the market is poised for growth, driven by rising awareness and the potential for improved patient outcomes in GBM management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies

Global Glioblastoma Multiforme Treatment Market Size by Treatment Type & CAGR (2024-2031)

• Market Overview
• Chemotherapy
  • Temozolomide
  • Bevacizumab
  • Carmustine
  • Lomustine
  • Others
• Radiation Therapy
  • External Beam Radiation Therapy (EBRT)
  • Brachytherapy
• Targeted Therapy
  • Monoclonal Antibodies
  • Tyrosine Kinase Inhibitors
• Immunotherapy
  • Checkpoint Inhibitors
  • Vaccine Therapy
• Tumor Treating Fields (TTF) Therapy
• Surgery
  • Craniotomy
  • Biopsy

Global Glioblastoma Multiforme Treatment Market Size by End User & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Research Institutes

Global Glioblastoma Multiforme Treatment Market Size & CAGR (2024-2031)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Dainippon Pharma Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation